Recent Updates
Recently added Catalysts

BED003

Phase 2

Colorectal Cancer | Small molecule | Other |Medpace Holdings, Inc. Common Stock|Last Updated: Sep 15, 2026

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

UNCONTROLLEDBiomarker
Total Trials1
Total Enrollment71

FDA Designations

No designations recorded

Clinical trial landscape

BED003 · 1 trial · 5 indications

Phase 2 1
NCT07702292[68Ga]BED003 PET Imaging of Fibroblast Activation Protein in Selected Oncology IndicationsColorectal Cancer
RECRUITING71 Analytics
PHASE2RECRUITING
[68Ga]BED003 PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
Colorectal Cancer
NCT0770229271
Unlock trial analytics

Study Endpoints

Primary Endpoints

Assess the diagnostic performance of [68Ga]BED003 in the peritoneum.
Until completion of follow-up procedures, up to 42 days post injection.

Assess the diagnostic performance of \[68Ga\]BED003 in the peritoneum.

Secondary Endpoints

Further assess the diagnostic performance of [68Ga]BED003.
Until completion of follow-up procedures, up to 42 days post injection
Semiquantitative assessment of [68Ga]BED003 tumour uptake.
Immediately following administration of [68Ga]BED003
Evaluate the safety and tolerability of [68Ga]BED003.
From screening until safety follow-up (48 hours post injection).
Unlock Study Endpoints

Study Design & Arms

AllocationNA
MaskingNONE
ModelSINGLE_GROUP
PurposeDIAGNOSTIC

Treatment Arms

ArmTypeDescription
[68Ga]BED003EXPERIMENTALEach participant will receive \[68Ga\]BED003 followed by positron emission tomography (PET)/computed tomography (CT) imaging at the PET/CT imaging visit (Visit 2).

Interventions

NameTypeDescription
[68Ga]BED003DRUGPositron emission tomography (PET)/computed tomography (CT) imaging
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to 79 Years
SexALL
Healthy VolunteersNo
Study Sites6

Inclusion Criteria: 1. Participants provide informed consent and confirm that they are able and willing to comply with all protocol requirements. 2. Participants must be ≥ 18 years and \< 80 years of age and competent to give informed consent. 3. Eastern Cooperative Oncology Group performance statu...

Countries:ItalyNetherlands
Unlock Eligibility Criteria

Competitive Landscape -Colorectal Cancer 257 trials

Top 20 of 71 competitors

CompanyTickerTrialsLead PhaseDrugs
AbbVie, Inc.ABBV8PHASE3Telisotuzumab Adizutecan, ABBV-400, Azirkitug, Budigalimab
Bristol-Myers Squibb CompanyBMY7PHASE3Ipilimumab, Nivolumab, Adagrasib, Pumitamig, BMS-986340
Merck & Co., Inc.MRK6PHASE3Pembrolizumab, Calderasib, MK-4830, Sacituzumab tirumotecan
Johnson & JohnsonJNJ5PHASE3Amivantamab, JNJ-89402638, JNJ-95437446
Pfizer Inc.PFE10PHASE3PF-08634404, Bevacizumab, Tucatinib, Trastuzumab, tisotumab vedotin
GSK plc Sponsored ADRGSK6PHASE3Dostarlimab, GSK4418959, GSK5460025
Summit Therapeutics IncSMMT3PHASE3Ivonescimab
Exelixis, Inc.EXEL5PHASE3Zanzalintinib, Cabozantinib
Agenus Inc.AGEN4PHASE3Balstilimab, Botensilimab, AGEN2034
Incyte CorporationINCY2PHASE3INCA33890, Ruxolitinib
Amgen Inc.AMGN1PHASE3Sotorasib, Panitumumab, Bevacizumab-awwb
Eli Lilly and CompanyLLY8PHASE2LY2157299, LY4066434, Cetuximab, Gemcitabine, Pemetrexed
AstraZeneca PLCAZN8PHASE2Datopotamab deruxtecan, Volrustomig, Rilvegostomig, FPI-2053, FPI-2107
Takeda Pharmaceutical Co. Ltd. Sponsored ADRTAK5PHASE2fruquintinib
BioNTech SE Sponsored ADRBNTX3PHASE2Autogene cevumeran, Pumitamig, BNT314
Novartis AG Sponsored ADRNVS7PHASE2Dabrafenib, trametinib, Opnurasib, TNO155, DKY709
Regeneron Pharmaceuticals, Inc.REGN2PHASE2Cemiplimab
Revolution Medicines, Inc.RVMD7PHASE1Elironrasib, Daraxonrasib, Zoldonrasib, RMC-5127
Jazz Pharmaceuticals Public Limited CompanyJAZZ2PHASE2Zanidatamab
Cardiff Oncology, Inc.CRDF1PHASE2Onvansertib
Unlock Competitive Intelligence